Evidence map›Paper›PMID 35992747›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2022

Complement-Binding Donor-Specific Anti-HLA Antibodies: Biomarker for Immunologic Risk Stratification in Pediatric Kidney Transplantation Recipients.

Vaka K Sigurjonsdottir, Natasha Purington, Abanti Chaudhuri, Bing M Zhang, Marcelo Fernandez-Vina, Runolfur Palsson, Neeraja Kambham, Vivek Charu, Kim Piburn, Lynn Maestretti and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Clinical characteristics of 15 cases of renal transplantation with preZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Vaka K SigurjonsdottirDivision of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, United States.
Natasha PuringtonQuantitative Sciences Unit, Department of Medicine, Stanford University, Palo Alto, CA, United States.
Abanti ChaudhuriDivision of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, United States.
Bing M ZhangHistocompatibility and Immunogenetics Laboratory, Stanford Blood Center, Stanford University, Palo Alto, CA, United States.
Marcelo Fernandez-VinaHistocompatibility and Immunogenetics Laboratory, Stanford Blood Center, Stanford University, Palo Alto, CA, United States.
Runolfur PalssonFaculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
Neeraja KambhamDepartment of Pathology, Stanford University, Palo Alto, CA, United States.
Vivek CharuDepartment of Pathology, Stanford University, Palo Alto, CA, United States.
Kim PiburnDivision of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, United States.
Lynn MaestrettiDivision of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, United States.
Anika ShahHistocompatibility and Immunogenetics Laboratory, Stanford Blood Center, Stanford University, Palo Alto, CA, United States.
Amy GalloDivision of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, United States.
Waldo ConcepcionTransplantation Services, Mohamed Bin Rashid University, Dubai, United Arab Emirates.
Paul C GrimmDivision of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, United States.
Division of Chemistry · USStanford University · USMohammed Bin Rashid University of Medicine and Health Sciences · AEUniversity of Iceland · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-mediated rejection is a common cause of early kidney allograft loss but the specifics of antibody measurement, therapies and endpoints have not been universally defined. In this retrospective study, we assessed the performance of risk stratification using systematic donor-specific antibody (DSA) monitoring. Included in the study were children who underwent kidney transplantation between January 1, 2010 and March 1, 2018 at Stanford, with at least 12-months follow-up. A total of 233 patients were included with a mean follow-up time of 45 (range, 9-108) months. Median age at transplant was 12.3 years, 46.8% were female, and 76% had a deceased donor transplant. Fifty-two (22%) formed C1q-binding

Indexed as

Complement C1qKidney TransplantationAntibodiesAntilymphocyte SerumBiomarkersChildFemaleGraft RejectionGraft SurvivalHLA AntigensHumansMaleRetrospective StudiesRisk AssessmentAntibodiesAntilymphocyte SerumBiomarkersComplement C1qHLA Antigensantibody-mediated rejectionchildrenimmunosuppressionkidney allografttransplant outcomes

Identifiers

PMID35992747
PMCPMC9386741
OpenAlexW4280521189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.